Physician profile
Yousaf Shaikh
NPI 1710397740
$4,783.50
in general payments reported to CMS, 2019-2025
26 companies · $1,417 in 2025
The $1,417 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.84 · 2021: $282 · 2022: $860 · 2023: $1,140 · 2024: $1,068 · 2025: $1,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,511 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,511.10 |
| Education | $113.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,030.76 | 2021-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $792.62 | 2021-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $582.47 | 2021-2025 | Entyvio, Gattex |
| Celgene Corporation | $375.51 | 2021-2023 | Zeposia |
| Ardelyx, INC. | $228.22 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.59 | 2021-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $203.29 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $194.63 | 2024 | Sucraid |
| Madrigal Pharmaceuticals | $166.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $157.65 | 2025 | Livdelzi |
| Genzyme Corporation | $123.84 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $123.77 | 2021-2023 | Ocaliva |
| Fresenius Kabi USA, LLC | $82.54 | 2023 | Idacio |
| Regeneron Healthcare Solutions, INC. | $70.91 | 2022-2024 | Dupixent |
| Ferring Pharmaceuticals INC. | $69.61 | 2022-2024 | Rebyota |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $54.49 | 2021-2023 | |
| Pfizer INC. | $52.86 | 2022-2025 | |
| Lilly USA, LLC | $49.22 | 2024-2025 | Omvoh |
| Alexion Pharmaceuticals, INC. | $48.30 | 2024 | Ultomiris |
| Ironwood Pharmaceuticals, INC | $41.60 | 2022-2023 | Linzess |
| Erbe USA INC | $32.48 | 2019-2021 | |
| Organon LLC | $28.52 | 2023 | Renflexis |
| Braintree Laboratories, INC. | $21.05 | 2025 | Sutab, Suflave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.54 | 2023 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2022 | |
| Redhill Biopharma INC. | $14.95 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yousaf Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.